TPST
- Tempest Therapeutics, Inc.
()
Overview
Company Summary
Tempest Therapeutics, Inc. (TPST) is a biotechnology company that focuses on developing novel therapeutics for the treatment of cancer and other diseases. The company combines expertise in immunology, small molecule chemistry, and cancer biology to create innovative therapies targeting various immune cell pathways.
Tempest Therapeutics is particularly dedicated to modulating the body's immune system response, with a focus on immune cells known as myeloid cells. These cells play a crucial role in regulating immune responses and have been identified as potential targets for therapeutic interventions.
One of the key areas of research for Tempest Therapeutics is myeloid cell regulation through a class of cell surface receptors known as TAM receptors. TAM receptors have been linked to the suppression of anti-tumor immune responses. The company develops small molecule drugs that can selectively and potently inhibit these receptors, boosting the body's immune system to fight against cancers and other diseases.
In addition to its focus on the immune system, Tempest Therapeutics also utilizes its proprietary drug discovery platform to identify novel targets and develop small molecule candidates that can modulate these targets. This platform integrates advanced technologies such as high-throughput screening, structure-based drug design, and computational chemistry.
Overall, Tempest Therapeutics aims to bring breakthrough therapies to patients by leveraging its expertise in immunology, small molecule chemistry, and drug discovery techniques. By targeting specific immune pathways and myeloid cell regulation, the company seeks to improve the treatment options available for patients battling cancer and other diseases.